In this paper, we demonstrated that TTI-101, a small-molecule STAT3 inhibitor currently under investigation in a three-arm, Phase II trial for treatment of hepatocellular carcinoma, markedly reduced adenoma numbers in the AOM-DSS mouse model of CRC and was well tolerated. Here, STAT3 is linked to colorectal carcinoma.